1. ALLA AKTIER
  2. NYHETER
  3. LIDDS

LIDDS

Nyheter LIDDS Nyheter alla bolag

LIDDS has concluded the acquisition of Noviga

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company has concluded the acquisition of Noviga Research AB, which was approved by the Extraordinary General Meeting in LIDDS on 27 February 2024.

In connection with the closing of the acquisition, LIDDS’s website has been updated, please see https://liddspharma.com/en/about-lidds/noviga-research/.

For additional information, please contact

Jenni Björnulfson, CEO and CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. LIDDS offers the NanoZolid technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS has concluded the acquisition of Noviga

Datum 2024-03-21, kl 12:05
Källa MFN
Bifogade filer
LIDDS has concluded the acquisition of Noviga
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!